Open AccessP112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
Author(s) -
Mei Matthew,
Palmer Joycelynne,
Maddocks Kami,
Martin Peter,
Tsai NiChun,
Smith Eileen,
Popplewell Leslie,
Armenian Saro,
Shouse Geoffrey,
Chen Robert,
Kwak Larry,
Rosen Steven T.,
Forman Stephen,
Bond David,
Herrera Alex F.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000891016.06930.34
Subject(s) - brentuximab vedotin , medicine , ibrutinib , refractory (planetary science) , oncology , bruton's tyrosine kinase , lymphoma , clinical endpoint , cohort , phases of clinical research , antibody drug conjugate , clinical trial , tyrosine kinase , immunology , hodgkin lymphoma , antibody , monoclonal antibody , leukemia , physics , receptor , chronic lymphocytic leukemia , astrobiology